1Yagoda A. Ahi-Bached B, Petrylak D. Chemotherapy for advanced renal cell carcinoma: 1983-1993[J].Semin Oncol, 1995.22(1): 42-60.
2Lopez-Hanninen E. Kirchner H. Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma:risks and benefits in 215 consecutive single institution Urol, 1996. 155(1): 19-25.
3Inoue T, Ohyama C, Hatakeyama S, et al. Active combination immunochemotherapy with interferon alpha, interleukin 2 and gemcitabine for four patients with metastatic renal cell carcinoma[J].Hinyokika Kiyo, 2005, 51(3):165-169.
4George C M, Vogelzang N J, Rini B I, et al. A phase Ⅱ trial of weekly intravenous gemcitabinc and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma[J].Ann Oncol, 2002, 13(1): 116-120.
5Porta C, Zimatore M, Imarisio I. et al. Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single institution Phase Ⅱ study[J].Cancer, 2004, 100(10): 2132-2138
6Yip D, Karap, etis C, Strickland A H. et al. A dose escalating study of oral eniluracil/5- fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies[J].Ann Oncol,2003. 14(6) :864-866.
7Jamieson S M. l.iu J, Hsu T, et al. Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity[J].Br J Cancer, 2003. 88(12):1942-1947.
